FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study

被引：0
作者：
Alberto Zaniboni
Enrico Aitini
Sandro Barni
Daris Ferrari
Stefano Cascinu
Vincenzo Catalano
Giuseppe Valmadre
Domenica Ferrara
Enzo Veltri
Claudio Codignola
Roberto Labianca
机构：
[1] Fondazione Poliambulanza,Medical Oncology Unit
[2] C. Poma Hospital,Medical Oncology Unit
[3] Treviglio-Caravaggio Hospital,Medical Oncology Unit
[4] S. Paolo Hospital,Medical Oncology Unit
[5] Università Politecnica delle Marche,Medical Oncology Unit
[6] Ospedali Riuniti di Ancona,Medical Oncology Unit
[7] Ospedali Riuniti Marche Nord,Medical Oncology DH
[8] Presidio San Salvatore,Medical Oncology Unit
[9] Ospedale di Sondalo,Medical Oncology Unit
[10] Ospedale San Carlo,Department of Surgery
[11] Ospedale Don Luigi di Liegro,Medical Oncology Unit
[12] Fondazione Poliambulanza,undefined
[13] Ospedali Riuniti,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词：
Pancreatic cancer; FOLFIRI; Chemotherapy; Second-line; Irinotecan;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1641 / 1645
页数：4
相关论文
共 176 条
  • [1] Bilimoria KY(2007)National failure to operate on early stage pancreatic cancer Ann Surg 246 173-180
  • [2] Bentrem DJ(2010)Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study J Clin Oncol 28 1645-1651
  • [3] Ko CY(2005)Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial J Clin Oncol 23 3509-3516
  • [4] Stewart AK(2007)Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 1960-1966
  • [5] Winchester DP(2009)Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer J Clin Oncol 27 5513-5518
  • [6] Talamonti MS(2011)FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 1817-1825
  • [7] Colucci G(2011)FOLFIRINOX: a small step or a great leap forward? J Clin Oncol 29 3727-3729
  • [8] Labianca R(2008)The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer Future Oncol 4 41-50
  • [9] Di Costanzo F(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-247
  • [10] Gebbia V(1989)Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1-10
12345678910